The growing number of clinics marketing stem cell therapies that are inadequately supported by evidence of safety and efficacy is a matter of ongoing concern. Researchers and scientific societies (notably ISCT) have worked to raise awareness and regulatory agencies have taken action in some cases, yet the proliferation of clinics continues. Some have suggested using consumer protection laws as another potential tool, focusing on the claims that clinics make in marketing their services. Most jurisdictions have laws that prohibit false or deceptive advertising, and this could provide a mechanism by which to hold clinics accountable and prevent patients from being induced to spend significant sums of money and put themselves at risk to try treatments that have little or no benefit and may be harmful.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Cytotherapy
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect